Q3 2026 lobbying Filed Oct 20
Q3 spend$120KQ2 $120K
QoQ0.0%vs Q2 2026
YoYn/avs Q3 2025
Agencies1+ House, Senate
HCRHealth IssuesPHAPharmacy
Lobbied on Developing cell and gene therapies for patients, Stiff Person Syndrome, rare disease, and multiple sclerosis; Outreach cell therapies for autoimmune diseases
No member trades in 90 days Stock page ›